— Know what they know.
Not Investment Advice

950160.KQ

Kolon TissueGene, Inc.
1W: +1.6% 1M: +5.7% 3M: +115.1% YTD: +9.4% 1Y: +248.6% 3Y: +997.6%
₩119,800.00 ($79.63)
+17500.00 (+17.11%)
 
KOE · Healthcare · Biotechnology · ₩8.51T
Smart Money Score
No convergence signal
Key Statistics
Market Cap₩8.51T ($5.7B)
52W Range31250-118900
Volume521,947
Avg Volume525,350
Beta0.13
Dividend
Analyst Ratings
No analyst coverage
About Kolon TissueGene, Inc.

Kolon TissueGene, Inc. is a biopharmaceutical company, which engages in the development of clinical-stage cell therapies for osteoarthritis. It offers TG-C, a platform technology that consists of a combination of allogeneic primary cells combined with genetically modified cells. The company was founded by Kwan H. Lee on June 9, 1999 and is headquartered in Rockville, MD.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms